Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Larimar Therapeutics, Inc. (ZFGN)
|
Add to portfolio |
|
|
|
| Price: |
$13.38
| | Metrics |
| OS: |
43.3
|
M
| |
|
|
| Market cap: |
$579
|
M
| |
|
|
|
Net cash:
|
$104
|
M
| |
$2.41
|
per share
|
|
EV:
|
$475
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 24.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 36.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -12.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | -50.6% | | | | | | | |
| Selling, general and administrative | | 50.5 | 42.8 | | | | | |
| Research and development | | | | 20.8 | 47.9 | 40.8 | 39.9 | 54.6 |
| General and administrative | 12.3 | | | 2.4 | 13.2 | 12.2 | 18.3 | 19.2 |
| EBIT | -36.5 | -50.8 | -42.2 | -23.2 | -61.1 | -53.0 | -58.2 | -73.8 |
| EBIT margin | -150.6% | | | | | | | |
| Pre-tax income | -35.4 | -50.6 | -42.5 | -23.2 | -61.4 | -52.0 | -57.9 | -74.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -35.4 | -50.6 | -42.5 | -23.1 | -61.4 | -52.0 | -57.9 | -74.3 |
| Net margin | -145.8% | | | | | | | |
| |
| Diluted EPS | ($1.37) | ($2.95) | ($3.57) | ($3.80) | ($1.90) | ($1.90) | ($2.12) | ($2.78) |
| Shares outstanding (diluted) | 25.8 | 17.2 | 11.9 | 6.1 | 32.2 | 27.4 | 27.3 | 26.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|